文献速递糖尿病肥胖与代谢综合征

灭火:通过靶向肥胖治疗来治疗儿童2型糖尿病

Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment.
PubMed 文献 · Diabetes Care · 2025-01-01

本文综述了针对肥胖治疗儿童2型糖尿病(T2D)的日益增多的证据。成人T2D中肥胖药物和减重手术可显著减重、改善血糖并减少降糖药使用;儿童中也有有限但增多的类似获益证据,减重手术可带来显著的3年和10年糖尿病缓解率。需进一步研究确定肥胖疗法和减重手术对儿童T2D进展和结局的长期影响。

要点

  • 儿童肥胖影响美国近五分之一儿童,是青年起病T2D发生和进展的关键驱动因素。
  • 成人T2D中肥胖药物和减重手术可显著减重、改善血糖并减少降糖药使用;儿童中证据有限但增多。
  • 美国食品药品监督管理局批准的肥胖药物在肥胖儿童中有效且耐受良好;减重手术在T2D儿童中可带来显著的3年和10年糖尿病缓解率。

核心结论

  • 针对肥胖治疗可能使儿童T2D缓解,并大幅改善血糖异常和胰岛素敏感性。
  • 儿童T2D中优先治疗肥胖的举措有限,尽管肥胖在糖尿病病理生理中起作用。
  • 需进一步研究确定肥胖疗法和减重手术对青年起病T2D进展和结局的长期影响。

研究设计与样本

  • 综述,描述支持针对肥胖治疗儿童T2D的日益增多的证据。

主要发现

  • 儿童肥胖影响美国近五分之一儿童,是青年起病T2D发生和进展的关键驱动因素。
  • 成人T2D中,在糖尿病治疗方案中加入肥胖药物和减重手术可显著减重、改善血糖异常并减少降糖药使用。
  • 儿童中,有有限但增多的证据显示相同的获益。
  • 美国食品药品监督管理局批准的肥胖药物在肥胖儿童中有效且耐受良好,是T2D合并肥胖儿童的重要治疗工具。
  • 几种药物已显示临床显著减重,并改善胰岛素抵抗和血糖异常。

临床怎么用

  • 作者认为,针对肥胖治疗是治疗儿童T2D的策略,但儿童中优先治疗肥胖的举措有限。
  • 作者指出,美国食品药品监督管理局批准的肥胖药物是T2D合并肥胖儿童的重要治疗工具。

局限性

  • 儿童中肥胖药物和减重手术获益的证据有限但增多。
  • 需进一步研究确定肥胖疗法和减重手术对青年起病T2D进展和结局的长期影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Childhood obesity affects nearly one in five children in the U.S. and is a key driver in youth-onset type 2 diabetes (T2D) development and progression. Effective obesity treatment may lead to T2D remission and can greatly improve dysglycemia and insulin sensitivity. The main objective of this article is to describe the growing evidence in support of targeting obesity to treat T2D in youth. There is growing evidence and guidance that for adults with T2D medical and surgical treatments for obesity should be prioritized. Yet, for youth with T2D, there has been limited movement to prioritize treating obesity, despite its role in diabetes pathophysiology. In adults, addition of obesity medications and bariatric surgery to the diabetes treatment regimen results in substantial weight reduction, improvement in dysglycemia, and decreased use of diabetes agents. In youth, there is limited, yet mounting evidence of these same benefits. U.S. Food and Drug Administration-approved obesity medications are effective and well tolerated in youth with obesity and an important therapeutic tool for youth with T2D and obesity. For several medications clinically significant weight reduction has been demonstrated, with improvement in insulin resistance and dysglycemia. In youth with T2D significant weight reduction has been demonstrated with bariatric surgery, with significant 3- and 10-year diabetes remission rates. Further studies in pediatric patients with T2D and obesity are needed to determine the long-term impacts of obesity therapies and bariatric surgery on progression and outcomes of youth-onset T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bensignor MO, Hsia DS, Van Name MA, et al. Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment. Diabetes Care. 2025. PMID: 40730197. doi:10.2337/dci25-0031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。